research use only
Cat.No.S2907
| Related Targets | PKC ROCK Bcr-Abl |
|---|---|
| Other TGF-beta/Smad Inhibitors | SB431542 RepSox (E-616452) Vactosertib (TEW-7197) LDN-193189 A-83-01 LDN-193189 Dihydrochloride Galunisertib (LY2157299) SRI-011381 (C381) LY2109761 SIS3 Hydrochloride |
| Cell Lines | Assay Type | Concentration | Incubation Time | Formulation | Activity Description | PMID |
|---|---|---|---|---|---|---|
| HFL1 cells | Function assay | 48 h | Antifibrotic activity in HFL1 cells assessed as inhibition of cell viability after 48 hrs by sulforhodamine B assay, IC50 = 0.71 μM. | 26896707 | ||
| LNCaP | Cell growth assay | 0, 0.1, 0.3 mg/ml | 3 days | PFD treatment significantly suppressed the growth of cells at 0.3 mg/ml | 30621175 | |
| PC-3 | Cell growth assay | 0, 0.1, 0.3 mg/ml | 3 days | PFD treatment significantly suppressed the growth of cells at 0.3 mg/ml | 30621175 | |
| E9 | Cell growth assay | 0, 0.1, 0.3 mg/ml | 3 days | PFD treatment significantly suppressed the growth of cells at 0.3 mg/ml | 30621175 | |
| F10 | Cell growth assay | 0, 0.1, 0.3 mg/ml | 3 days | PFD treatment significantly suppressed the growth of cells at 0.3 mg/ml | 30621175 | |
| AIDL | Cell growth assay | 0, 0.1, 0.3 mg/ml | 3 days | PFD treatment significantly suppressed the growth of cells at 0.3 mg/ml | 30621175 | |
| human intestinal fibroblasts (HIFs) | Function assay | 1 h | PFD inhibits HIFs differentiation and the collagen deposition induced by TGF-β1. | 30152848 | ||
| Click to View More Cell Line Experimental Data | ||||||
|
In vitro |
DMSO
: 37 mg/mL
(199.76 mM)
Ethanol : 37 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 185.22 | Formula | C12H11NO |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 53179-13-8 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | S-7701, AMR-69 | Smiles | CC1=CN(C(=O)C=C1)C2=CC=CC=C2 | ||
| Targets/IC50/Ki |
TGF-β
(Cell-free assay) |
|---|---|
| In vitro |
Pirfenidone (< 300 μg/mL) suppresses the proinflammatory cytokine tumor necrosis factor-α (TNF-α) by a translational mechanism in RAW264.7 cells, which is independent of activation of the mitogen-activated protain kinase (MAPK) 2, p38 MAP kinase, and c-Jun N-terminal kinase (JNK). This compound (< 10 mM) leads to reduced glioma cell density in concentration-dependent manner in LN-18, T98G, LNT-229 and LN-308 cell lines. It (< 5 mM) reduces TGF-β bioactivity by affecting TGF-β2 mRNA expression and processing of pro-TGF-β in CCL-64 cells. This chemical (< 8.3 mM) inhibits the activity of recombinant furin and downregulates the expression of MMP-11 in a dose-dependent manner in LN-308 cells. |
| In vivo |
Pirfenidone (250 mg/kg) potently inhibits the production of the proinflammatory cytokines, TNF-alpha, interferon-gamma, and interleukin-6, but enhances the production of the anti-inflammatory cytokine, interleukin-10, in mice. This compound (250 mg/kg/day) ameliorates cyclosporine-induced fibrosis by about 50% and decreases TGF-beta1 protein expression by 80% in Sprague-Dawley rats receiving a low-salt diet. It (400 mg/kg/day) inhibits heat shock protein 47-positive cells and myofibroblasts, the principal cells responsible for the accumulation and deposition of extracellular matrix seen in pulmonary fibrosis in ICR mice intravenously injected with bleomycin. This chemical (0.5%, liquid diet) treatment reduces the degree of liver injury in rats, as determined by alanine aminotransferase values and necro-inflammatory score, which is associated with reduced hepatic stellate cells proliferation and collagen deposition. This compound (0.5%, liquid diet) administration downregulates dimethylnitrosamine induced transcripts levels of procollagen alpha1(I), TIMP-1 and MMP-2 by 50-60% in rats, and this is associated with a 70% reduction in collagen deposition. |
References |
|
| Methods | Biomarkers | Images | PMID |
|---|---|---|---|
| Immunofluorescence | α-SMA SMAD4 / SMAD2 / SMAD3 F-actin / β-catenin / Vimentin |
|
22132230 |
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05676112 | Withdrawn | Pulmonary Fibrosis |
Boehringer Ingelheim|China-Japan Friendship Hospital |
December 29 2023 | -- |
| NCT06070610 | Completed | Healthy |
Boehringer Ingelheim |
November 8 2023 | Phase 1 |
| NCT05713292 | Active not recruiting | COVID-19 Pneumonia |
Capital Medical University |
December 30 2022 | Phase 3 |
| NCT05505409 | Recruiting | Pirfenidone|Connective Tissue Diseases|Interstitial Lung Disease |
Qilu Hospital of Shandong University |
June 22 2022 | Phase 4 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
Question 1:
I'd like to know how to use your 50mg dose of it to make a solution for intraperitoneal injection in a mouse. Could you give me some advice?
Answer:
For I.P. injection, it can be dissolved in 2% DMSO+30% PEG 300+ddH2O at 10 mg/ml clearly. When preparing the solution, please dissolve this compound in DMSO clearly first. Then add PEG, after they mixed well, then dilute with water.